Considering that the study was designed as a real-life study and SGLT2 inhibitors are recommended with a strong level of evidence for the treatment of T2D with cardiorenal risk factors, recruitment bias could not be avoided. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.